113 results
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
9 May 24
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
7:36pm
had $42.8 million of cash and cash equivalents, $106.8 million of short-term investments, and $8.8 million of long-term investments. In addition, in May … equivalents, short-term and long-term investments during the three months ended March 31, 2024, compared to the three months ended March 31, 2023.
Net
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
of its capital stock, (ii) there has not been any material change in the capital stock or long-term or short-term debt of the Company or its … thereto), there shall not have been any change in the capital stock or long-term or short-term debt of the Company or the Subsidiaries or any change
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
and sought continued treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension Study (C602). Top line results from DESTINY … observed in two of three key secondary endpoints. Subjects who complete the DESTINY PWS study were allowed to enroll in a long-term, safety extension
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
treatment with DCCR were eligible to receive DCCR in a long-term open-label safety extension Study (C602). Top line results from DESTINY PWS were … in two of three key secondary endpoints. Subjects who complete the DESTINY PWS study were allowed to enroll in a long-term, safety extension study (C602
8-K
EX-99.1
60f9wi
7 Mar 24
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
6:06am
S-3ASR
8opnk
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-1.2
x9uvmxsxq gqt
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
av4bd7g4f86myz70
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
ir7qlwfi0bxq x5sirf
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
cmi07c3j
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
p3yq8548hj79i5 6pqhh
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
EX-99.1
t9rc3
8 Aug 23
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:25pm